arrow
L

Laetitia Mauti

cantonal hospital winterthur
H指数:8
被引数:628

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Decision-Making in Intrathecal Therapy for Leptomeningeal Disease

脑膜癌病鞘内治疗中的决策制定

2026-05-010
PRE
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

曲妥珠单抗德鲁替康(Trastuzumab Deruxtecan)在HER2突变非小细胞肺癌患者中的全身及颅内疗效与安全性:来自TRACER/HERTras真实世界队列的证据

2026-02-240
OAAI
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

性别特异性的疗效和安全性结局:在接受新辅助治疗的可切除III期非小细胞肺癌(NSCLC)患者中的联合分析——SAKK试验16/96、16/00、16/01、16/08和16/14

2025-11-100
OAAI
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

一线免疫治疗±化疗,联合或不含 upfront 立体定向放射治疗(SRT)在无症状脑转移的非小细胞肺癌(NSCLC)患者中的应用

2025-11-030
PRE
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025-09-300
OAAI
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP 25-23 ADOPT-lung:一项国际、多中心、开放标签的随机III期试验,旨在评估在术前新辅助化疗联合durvalumab的基础上,为可切除的IIB-IIIB(N2)期非小细胞肺癌(NSCLC)患者添加辅助durvalumab治疗的获益。

2025-06-230
OA
Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment-A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report

接受新辅助治疗后未进行根治性手术的可切除III期NSCLC患者的结局——SAKK试验16/96、16/00、16/01、16/08和16/14的回顾性分析:简报

2025-06-010
OAAI
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

SCLC的一线化学免疫疗法: 一项两国现实世界研究的结果

2025-01-010
OA
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

接受Ipilimumab和Nivolumab联合作为一线或后续治疗的恶性胸膜间皮瘤患者的真实结果

2024-12-010
OA